Literature DB >> 7246583

Urinary excretion of reduced metabolites of digoxin.

J Lindenbaum, D Tse-Eng, V P Butler, D G Rund.   

Abstract

The urinary excretion of the relatively cardioinactive reduced metabolites of digoxin, dihydrodigoxin and related compounds was measured by radioimmunoassay in 131 normal subjects during studies of the bioavailability of digoxin preparations. Digoxin reduction products (DRP) constitute more than 5 percent of the excretion of digoxin and its metabolites in one-third of the volunteers after the administration of single or multiple doses of digoxin. There was little or no output of DRP during the first 8 hours after a single dose, with maximal excretion usually occurring on the second day. Most subjects who excreted more than 5 percent DRP on one occasion did so with each subsequent exposure to digoxin. Six volunteers, however, in whom substantial amounts of DRP had previously been found, failed to excrete detectable quantities after subsequent doses. In two, this change occurred shortly after they took erythromycin. Urinary DRP were less after the intravenous administration compared to the oral administration of digoxin. After oral doses, DRP excretion tended to vary inversely with the bioavailability of the preparation. The findings are consistent with the hypothesis that DRP are formed as the result of the activity of a variable component of the intestinal flora. Prospective studies will be necessary to prove this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7246583     DOI: 10.1016/0002-9343(81)90260-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

Review 1.  Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?

Authors:  Lingeng Lu; Yixing Wu; Lingjun Zuo; Xingguang Luo; Peter J Large
Journal:  World J Microbiol Biotechnol       Date:  2013-10-09       Impact factor: 3.312

Review 2.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 3.  Gut microbiota modulation of chemotherapy efficacy and toxicity.

Authors:  James L Alexander; Ian D Wilson; Julian Teare; Julian R Marchesi; Jeremy K Nicholson; James M Kinross
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-08       Impact factor: 46.802

Review 4.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

5.  Metabolism of digoxin after oral and intrajejunal administration.

Authors:  J O Magnusson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

6.  Metabolism of digoxin and absorption site.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; U E Jonsson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 7.  Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.

Authors:  A D Mooradian
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

8.  Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora.

Authors:  V I Mathan; J Wiederman; J F Dobkin; J Lindenbaum
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 9.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb

Review 10.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.